Gene description for CHD9 |
Gene name |
chromodomain helicase DNA binding protein 9 |
Gene symbol |
CHD9 |
Other names/aliases |
AD013 CHD-9 CReMM KISH2 PRIC320 |
Species |
Homo sapiens |
Database cross references - CHD9 |
ExoCarta |
ExoCarta_80205 |
Vesiclepedia |
VP_80205 |
Entrez Gene |
80205 |
HGNC |
25701 |
UniProt |
Q3L8U1
|
CHD9 identified in exosomes derived from the following tissue/cell type |
Prostate cancer cells
|
25844599
|
Prostate cancer cells
|
25844599
|
Gene ontology annotations for CHD9 |
|
Experiment description of studies that identified CHD9 in exosomes |
1 |
Experiment ID |
275 |
MISEV standards |
✔
EM
|
EV Biophysical techniques |
✔
TSG101|Alix|RAB5A|CD9|CD82|CD63|CD81
|
EV Enriched markers |
✔
AIF
|
EV Negative markers |
✔
NTA
|
EV Particle analysis
|
|
Identified molecule |
protein
|
Identification method |
Mass spectrometry
|
PubMed ID |
25844599
|
Organism |
Homo sapiens |
Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
Journal name |
Oncotarget
|
Publication year |
2015 |
Sample |
Prostate cancer cells |
Sample name |
DU145 - Docetaxel sensitive |
Isolation/purification methods |
Filtration Ultracentrifugation Sucrose density gradient |
Flotation density |
1.12-1.19 g/mL
|
Molecules identified in the study |
Protein |
Methods used in the study |
Mass spectrometry/Flow cytometry/Western blotting |
|
|
2 |
Experiment ID |
274 |
MISEV standards |
✔
EM
|
EV Biophysical techniques |
✔
TSG101|Alix|RAB5A|CD9|CD82|CD63|CD81
|
EV Enriched markers |
✔
AIF
|
EV Negative markers |
✔
NTA
|
EV Particle analysis
|
|
Identified molecule |
protein
|
Identification method |
Mass spectrometry
|
PubMed ID |
25844599
|
Organism |
Homo sapiens |
Experiment description |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. |
Authors |
Kharaziha P, Chioureas D, Rutishauser D, Baltatzis G, Lennartsson L, Fonseca P, Azimi A, Hultenby K, Zubarev R, Ullen A, Yachnin J, Nilsson S, Panaretakis T. |
Journal name |
Oncotarget
|
Publication year |
2015 |
Sample |
Prostate cancer cells |
Sample name |
DU145 - Docetaxel resistant |
Isolation/purification methods |
Filtration Ultracentrifugation Sucrose density gradient |
Flotation density |
1.13-1.18 g/mL
|
Molecules identified in the study |
Protein |
Methods used in the study |
Mass spectrometry Flow cytometry Western blotting |
|
|
Protein-protein interactions for CHD9 |
|
Protein Interactor |
ExoCarta ID |
Identification method |
PubMed |
Species |
No interactions are found.
|
|
Pathways in which CHD9 is involved |
|
|
|